Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Liliana Villanueva-Lizama"'
Autor:
Bárbara Carolina Arias-Argáez, Victor Manuel Dzul-Huchim, Ana Paulina Haro-Álvarez, Miguel Enrique Rosado-Vallado, Liliana Villanueva-Lizama, Julio Vladimir Cruz-Chan, Eric Dumonteil
Publikováno v:
PLoS ONE, Vol 18, Iss 10, p e0292520 (2023)
Chagas disease by Trypanosoma cruzi (T. cruzi) infection is a leading cause of myocarditis worldwide. Chagas cardiomyopathy is presented with a wide variety of conduction abnormalities including arrhythmias, first- and second-degree atrioventricular
Externí odkaz:
https://doaj.org/article/2bee7d73319d4555b2c2efeb87928807
Publikováno v:
Evolutionary Applications, Vol 13, Iss 10, Pp 2663-2672 (2020)
Abstract Introduction Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a major public health problem in the Americas, and existing drugs have severe limitations. In this context, a vaccine would be an attractive alternative for
Externí odkaz:
https://doaj.org/article/dbe85c82b5ae4da8afd5bf8f2d24cbef
Autor:
Juan Jose de la Cruz, Liliana Villanueva-Lizama, Victor Dzul-Huchim, María-Jesus Ramírez-Sierra, Pedro Martinez-Vega, Miguel Rosado-Vallado, Jaime Ortega-Lopez, Claudia Ivonne Flores-Pucheta, Portia Gillespie, Bin Zhan, Maria Elena Bottazzi, Peter J. Hotez, Eric Dumonteil
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 1, Pp 210-219 (2019)
A therapeutic vaccine for human Chagas disease (American trypanosomiasis caused by Trypanosoma cruzi) is under development based on the success of vaccinating mice with DNA constructs expressing the antigens Tc24 and Tc-TSA-1. However, because DNA an
Externí odkaz:
https://doaj.org/article/539cfa6032b84113ab27eea2495a768b
Autor:
Victor Dzul-Huchim, Andrea Alfaro-Chacón, Patricia Novelo-Sarabia, Miguel Rosado-Vallado, Julio Cruz-Chan, Antonio Euan-Canto, Julio Torres-Romero, Fabian Gusovsky, Jaime Ortega-Lopez, Peter Hotez, Maria Elena Bottazzi, Liliana Villanueva-Lizama, Vctor Arana-Argáez
Chagas disease is a chronic infection caused by Trypanosoma cruzi. The first-line drugs approved for treatment have several limitations and are associated with toxicity. The recombinant TSA-1-C4 and Tc24-C4 proteins have been profiled as promising ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13580ef1e8430e01b44dd21db05861de
https://doi.org/10.22541/au.167945777.72745278/v1
https://doi.org/10.22541/au.167945777.72745278/v1
